Conditions: Age-Related Memory Disorders
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 103
Healthy volunteers: no

Brief summary:
The purpose of the study is to determine the safety, tolerability, and effectiveness of 2 dose levels of LX6171 given over 28 days in patients with Age Associated Memory Impairment (AAMI).

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None

Interventions: intervention 1: LX6171 High Dose intervention 2: LX6171 Low Dose intervention 3: Placebo
Intervention descriptions: intervention 1: A high dose of LX6171, using an oral suspension; daily oral intake for 28 days in the morning at approximately the same time. intervention 2: A low dose of LX6171, using an oral suspension; daily oral intake for 28 days in the morning at approximately the same time. intervention 3: Matching placebo dosing with daily oral intake for 28 days in the morning at approximately the same time.

Protocol document: